BBIO vs DAL · rev $221.9M vs P/E 12, rev $61.64B
BridgeBio Pharma Inc (BBIO) versus Delta Air Lines Inc (DAL) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
BBIO currently screens at market cap $13.24B. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Not investment advice. Open the BBIO and DAL stock pages for the full models.
Not investment advice.